EE284 Cost-per-Remission of Vedolizumab vs. Risankizumab for the Treatment of Moderate-to-Severely Active Crohn’s Disease in Italy, France, and Canada
Abstract
Authors
Elizabeth Brook Chloë Hardern Jakob Langer Raffaella Viti Arnaud Nucit Cinira Lefevre Jun Yu Zhou